Alan Cohen, MD
Dr. Cohen is a veteran in clinical development for metabolic and rare diseases and a board-certified pulmonologist and pediatric subspecialist.
Chief Medical Officer & SVP of Monogenic Diseases
His research and drug development career have included leadership positions at both biotech and pharmaceutical companies, including BridgeBio/Eidos Therapeutics, Bayer, Eddingpharm (as CMO), Intermune (acquired by Roche/Genentech), Boehringer Ingelheim, and Jazz Pharmaceuticals (as CMO).
He is the author of over 100 peer-reviewed articles, abstracts, platform presentations, and book chapters in his areas of interest and expertise, including CF, microbiology, and cardiopulmonary disorders. He has remained clinically active in direct patient care for the majority of his more than 30-year medical career, most recently serving as adjunct clinical and teaching faculty at Stanford University School of Medicine in the Department of Pediatric Pulmonology.
Dr. Cohen received his MD from New York Medical College, before completing his residency and fellowship at the University of Colorado / National Jewish Center for Immunology and Respiratory Diseases.